Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 49706-2103; 59285-010; 66039-871; 31722-030; 43598-852; 45963-454; 45963-456; 67877-552; 69238-1703; 69452-161; 69539-200; 70700-271; 70771-1410; 70771-1471; 58032-2017; 0078-0468; 0078-0469; 31722-013; 43598-854; 69238-1488; 69452-159; 69539-023; 46708-410; 57664-768; 62332-324; 62756-568; 69539-021; 69539-073; 69539-199; 62332-412; 67877-550; 67877-553; 69097-391; 69097-560; 69539-022; 70771-1472; 65727-037; 0078-0655; 42806-371; 43598-851; 67877-554; 68462-495; 68462-496; 69097-392; 70710-1012; 62512-0078; 0078-0470; 0078-0654; 0078-0720; 31722-029; 43598-856; 46708-411; 46708-412; 69097-393; 69238-1486; 69539-303; 70710-1276; 72205-176; 14501-0049; 63278-1070; 65085-0063; 66022-0301; 0078-0656; 31722-031; 43598-855; 57664-769; 62332-325; 62756-569; 69539-075; 70710-1011; 72205-075; 72647-372; 74436-0323; 31722-012; 43598-853; 62332-326; 62332-411; 62756-570; 68462-494; 69097-570; 69238-1487; 69238-1702; 69238-1704; 70710-1013; 70771-1411; 70771-1473; 0591-3853; 72647-371; 0591-2961; 11722-040; 53104-7713; 59651-419; 0078-0727; 42806-372; 46708-324; 46708-325; 57664-770; 67877-549; 69539-074; 70700-270; 72205-076; 65015-738; 0078-0713; 31722-011; 42806-373; 45963-455; 46708-326; 62332-410; 67877-551; 69097-550; 69452-160; 70700-269; 70710-1275; 70710-1277; 70771-1409; 72647-373; 65372-1164
UNII V8G4MOF2V9
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual field defect17.17.01.001; 06.02.07.0030.001239%Not Available
Visual impairment06.02.10.0130.023791%Not Available
Vitamin D deficiency14.12.03.0030.003346%Not Available
Vomiting07.01.07.0030.191691%
Waldenstrom's macroglobulinaemia01.15.03.001; 16.28.03.0010.002478%Not Available
Wheezing22.03.01.009--
Yellow skin23.03.03.042; 09.01.01.009; 08.01.03.0460.002478%Not Available
Zinc deficiency14.13.01.0010.001239%Not Available
Pneumoperitoneum07.07.01.0080.002478%Not Available
Tubulointerstitial nephritis20.05.02.002--Not Available
Deafness unilateral04.02.01.0110.003098%Not Available
Hypoacusis04.02.01.0060.033208%
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Brain oedema17.07.02.003; 12.01.10.0100.001859%
General physical health deterioration08.01.03.0180.025402%Not Available
Erythropoiesis abnormal01.07.02.0100.001239%Not Available
Anal haemorrhage24.07.02.029; 07.12.03.0040.001859%
Shock haemorrhagic24.06.02.014; 14.05.05.0030.002478%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.003717%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.005204%
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.001859%Not Available
Hyperphosphaturia20.02.01.025; 14.04.03.0060.001859%Not Available
Post transplant lymphoproliferative disorder11.05.10.006; 01.13.02.004; 16.21.02.0040.001859%Not Available
Conjunctival hyperaemia06.04.01.0040.001239%Not Available
Lymphatic disorder01.09.01.003--Not Available
Detachment of retinal pigment epithelium06.09.03.0110.001239%Not Available
Large intestinal haemorrhage24.07.02.026; 07.12.03.0030.001239%
Deafness bilateral04.02.01.0070.001239%Not Available
Fanconi syndrome acquired20.05.03.012; 14.01.01.0130.018835%Not Available
Protein urine present13.13.02.006--Not Available
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 18 Pages